Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Investigator Initiated, International Multi-Centre, Multi-Arm, Multi-Stage Randomised Double Blind Placebo Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19

NCT05122182 is registered in ClinicalTrials.gov with University of Sydney as lead sponsor.

NCT NCT05122182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05122182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Investigator Initiated, International Multi-Centre, Multi-Arm, Multi-Stage Randomised Double Blind Placebo Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19
Lead sponsor
University of Sydney
Phase
Phase 2
Overall status
Terminated
Start date
January 7, 2022
Completion date
January 28, 2023
Enrollment
49 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov2 infection